Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production

COMMENTED

Rheumatoid Arthritis

Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

Clin Rheumatol.

Kunwar S, Collins CE, Constantinescu F

doi: 10.1007/s10067-018-4199-7.

Autoimmune DiseaseRheumatoid Arthritis

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis

BioDrugs.

Nakayamada S, Kubo S, Iwata S, Tanaka Y

doi: 10.1007/s40259-016-0190-5

Psoriatic ArthritisRheumatoid Arthritis

Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis

Rheumatology (Oxford).

Genovese MC, Weinblatt ME, Mease PJ, Aelion JA, Peloso PM, Chen K, Li Y, Liu J, Othman AA, Khatri A, Mansikka HT, Leszczynski P

doi: 10.1093/

Rheumatoid Arthritis

Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis.

Clin Exp Med.

Tong S, Liu J, Zhang C

doi: 10.1007/s10238-017-0449-2.

Further Publications Rheumatology

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis

Ann Rheum Dis

Fleischmann RM, Blanco R, Hall S, Thomson GTD, Van den Bosch FE, Zerbini C, Bessette L, Enejosa J, Li Y, Song Y, DeMasi R, Song IH

doi: 10.1136/annrheumdis-2020-218412

Rheumatoid Arthritis

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

Arthritis Rheumatol.

Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR

doi: 10.1002/art.39944.

Rheumatoid Arthritis

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

doi: 10.1016/S0140-

Rheumatoid Arthritis

A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients with Rheumatoid Arthritis

Arthritis Rheumatol.

Bach M, Moon J, Moore R, Pan T, Nelson JL, Lood C

doi: 10.1002/art.41062.

Allergic Diseases

Interleukin-4 receptor engagement in human neutrophils impairs their migration and extracellular trap formation

doi: 10.1016/j.jaci.2019.01.042.

Related content

Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials

Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis

Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis

Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis.

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients with Rheumatoid Arthritis

Interleukin-4 receptor engagement in human neutrophils impairs their migration and extracellular trap formation